Replies to post #128247 on Enzolytics Inc (ENZC)

[Timing101]

In the end .. this was so old way back when .. that is the reason Charles did the REINCORPORATOIN to the NEW ENZC, to put the major Legal Buffers
needed for items like this .
--
I go back to what I said before .. in any case this is Zhabilov Trust item of the OLD ENZC and it should be (even if there was some action for Dimitar Savov) with them (Harry and Diana) .
--
Savov has no case.. repeat as per Charles Crotopia 40 year accredited attorney ..NO CASE with the new and improved ENZC.
D. SAVOV is a perfect example of European Crooks , that is just how they roll and have been for decades in areas like that , plus he is in politics , it is their DNA to see how much they can get for nothing.
--
This is NOT THE REASON anything is going on with ENZC and for that matter just a minor hurdle which will be quickly overcome.

[Wisdom of Locke]

No real need to dig. Some existing info from previous ENZC documents: IMMB sold all of its assets to the entity that ended up being renamed Enzolytics. This included the worldwide licensing agreement issued from Zhabilov Trust the patent owner. (Harry Zhabilov was the inventor.) ENZC acquired 49% interest of IMMB BG. IMMB BG was issued a sub license for the Bulgarian territory and for the Ukraine when IMMB BG entered into the Omega agreement.

All agreements with IMMB BG were cancelled for failure to perform. The only license that is in place is the license granting exclusive rights to the patent to ENZC- including manufacturing rights.

Based on this license agreement between the Trust and ENZC, two distribution agreements have been entered into in 20021; one to the IMPL entity, which is paying for the clinical trials and EMA permitting cost and ENZC owns 50% and a second with an entity that is contributing 50% of a manufacturing facility in Bulgaria once the permit from the EMA is completed. I am sure neither of these two seasoned groups would have invested in a distributorship if there were any other license of the ITV-1 immunotherapy.